Literature DB >> 21553884

Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging.

Chung-Hsin Wang1, Yu-Fen Huang, Chih-Kuang Yeh.   

Abstract

Targeted ultrasound contrast agents can be prepared by some specific bioconjugation techniques. The biotin-avidin complex is an extremely useful noncovalent binding system, but the system might induce immunogenic side effects in human bodies. Previous proposed covalently conjugated systems suffered from low conjugation efficiency and complex procedures. In this study, we propose a covalently conjugated nanobubble coupling with nucleic acid ligands, aptamers, for providing a higher specific affinity for ultrasound targeting studies. The sgc8c aptamer was linked with nanobubbles through thiol-maleimide coupling chemistry for specific targeting to CCRF-CEM cells. Further improvements to reduce the required time and avoid the degradation of nanobubbles during conjugation procedures were also made. Several investigations were used to discuss the performance and consistency of the prepared nanobubbles, such as size distribution, conjugation efficiency analysis, and flow cytometry assay. Further, we applied our conjugated nanobubbles to ex vivo ultrasound targeted imaging and compared the resulting images with optical images. The results indicated the availability of aptamer-conjugated nanobubbles in targeted ultrasound imaging and the practicability of using a highly sensitive ultrasound system in noninvasive biological research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553884     DOI: 10.1021/la2011259

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  25 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 2.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Aptamer-based molecular imaging.

Authors:  Tianjiao Wang; Judhajeet Ray
Journal:  Protein Cell       Date:  2012-09-15       Impact factor: 14.870

4.  DNA Aptamer Technology for Personalized Medicine.

Authors:  Hang Xing; Kevin Hwang; Ji Li; Seyed-Fakhreddin Torabi; Yi Lu
Journal:  Curr Opin Chem Eng       Date:  2014-05-01       Impact factor: 5.163

Review 5.  Ultrasound imaging beyond the vasculature with new generation contrast agents.

Authors:  Reshani H Perera; Christopher Hernandez; Haoyan Zhou; Pavan Kota; Alan Burke; Agata A Exner
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-01-08

6.  Understanding Acoustic Cavitation Initiation by Porous Nanoparticles: Toward Nanoscale Agents for Ultrasound Imaging and Therapy.

Authors:  Adem Yildirim; Rajarshi Chattaraj; Nicholas T Blum; Andrew P Goodwin
Journal:  Chem Mater       Date:  2016-08-09       Impact factor: 9.811

Review 7.  Current progress of aptamer-based molecular imaging.

Authors:  Andrew Z Wang; Omid C Farokhzad
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

8.  Toward ultrasound molecular imaging with phase-change contrast agents: an in vitro proof of principle.

Authors:  Paul S Sheeran; Jason E Streeter; Lee B Mullin; Terry O Matsunaga; Paul A Dayton
Journal:  Ultrasound Med Biol       Date:  2013-02-27       Impact factor: 2.998

9.  Improving performance of nanoscale ultrasound contrast agents using N,N-diethylacrylamide stabilization.

Authors:  Reshani H Perera; Hanping Wu; Pubudu Peiris; Christopher Hernandez; Alan Burke; Helen Zhang; Agata A Exner
Journal:  Nanomedicine       Date:  2016-08-23       Impact factor: 5.307

10.  Stable Encapsulation of Air in Mesoporous Silica Nanoparticles: Fluorocarbon-Free Nanoscale Ultrasound Contrast Agents.

Authors:  Adem Yildirim; Rajarshi Chattaraj; Nicholas T Blum; Galen M Goldscheitter; Andrew P Goodwin
Journal:  Adv Healthc Mater       Date:  2016-03-15       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.